- |||||||||| EF-009 / Everfront Biotech
Trial completion date, Trial primary completion date: A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer (clinicaltrials.gov) - Feb 19, 2024
P1/2, N=30, Not yet recruiting,
Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Dec 2025
- |||||||||| EF-009 / Everfront Biotech
Trial completion date, Trial primary completion date: A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer (clinicaltrials.gov) - Jan 18, 2023
P1/2, N=30, Not yet recruiting,
Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Jun 2024 --> Dec 2025 Trial completion date: Jan 2024 --> Jun 2025 | Trial primary completion date: Jan 2023 --> Jun 2024
- |||||||||| EF-009 / Everfront Biotech
Trial completion date, Trial primary completion date: A Phase I/IIa Study of EF-009 in Patients With Pancreatic Cancer (clinicaltrials.gov) - Aug 18, 2021
P1/2, N=30, Not yet recruiting,
Trial completion date: Jan 2024 --> Jun 2025 | Trial primary completion date: Jan 2023 --> Jun 2024 Trial completion date: Feb 2023 --> Jan 2024 | Trial primary completion date: Feb 2021 --> Jan 2023
|
